Menu

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

Sep 13, 2018
Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.

CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media

CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media was formulated in response to customers' need for a more robust and stable resin that can maintain the superior performance of CHT resins. CHT XT offers high resolution and efficient single-step clearance of aggregates and other impurities such as HCP, dsDNA, endotoxins, and leached Protein A. It can be used in applications such as purification of enzymes, monoclonal and polyclonal antibodies of various classes, antibody fragments, and bispecific antibodies; efficient isolation and purification of viruses and virus-like particles (VLPs); and, separation of supercoiled DNA from linear duplexes as well as single-stranded from double-stranded DNA.

Key benefits of CHT XT Media

  • Unique selectivity — binds by cation exchange and affinity interactions, unlike any unimodal resin
  • Cost efficiency — reusability improves economy of the process purification workflow
  • Time efficiency — can be used for single-step clearance of aggregates and other impurities
  • Broad chemical compatibility — is compatible with a wide range of chemicals

To learn more about CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media, please visit bio-rad.com/CHT-XT.

Nuvia HP-Q Anion Exchange Resin

Nuvia HP-Q Anion Exchange Resin was introduced to fill customers’ need for a high-performance resin compatible with high-throughput (HTP) large biomolecule purification. It can be used for downstream purification of large molecules such as high molecular weight (HMW) plasma proteins IgA and IgM, viruses, VLPs, and PEGylated proteins.

Key benefits of Nuvia HP-Q Resin

  • Time efficiency and HTP compatibility — high flow rate compatibility (300 cm/hr) and fast mass transfer kinetics ensure purifications can be performed in less time
  • Cost efficiency — lifetime of more than 100 cycles without loss of dynamic binding capacity (DBC) allows repeated use
  • Mechanical stability — resin column holds up under the flow rates required for manufacturing-scale purification
  • High productivity — excellent DBC (>50 mg/ml) with optimized pore structure, spacer length, and ligand density improves productivity

To learn more about Nuvia HP-Q Anion Exchange Resin, please visit bio-rad.com/Nuvia HP-Q.

Both media will be on display at BioProcess International Conference & Exhibition in Boston, September 5–7. At the event Bio-Rad will also host daily Design of Experiment (DoE) Workshops in Booth 1617 to discuss best strategies for screening new resins and tools to facilitate experimental design. Highlights of DoE workshop include:

  • Introduction of new chromatography resins and best DoE practices
  • Discussion of new ChromLab 6.0 Software features
  • Exploration of how multivariable scouting with the NGC Chromatography System aids in DoE
  • Visualization of stain-free gels and western blots with the ChemiDoc MP Imaging System
  • Detection of impurities before and after purification with the Droplet Digital PCR System

To attend a DoE Booth Workshop, please visit bio-rad.com/BPIworkshop.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.